kotak-logo
Open Demat Account
Lincoln Pharmaceuticals Share Price

Lincoln Pharmaceuticals Share Price

608.15
-7.90 (-1.28%)
NSE
BSE
NSE: LINCOLN | BSE: 531633 | Pharmaceuticals | Small Cap| as on 21 Apr, 2026 • 03:29 PM IST
Buywith MTF at 1x leverage

Lincoln Pharmaceuticals Annualised Return

1 Year

▲5.33%

3 Years

▲15.28%

5 Years

▲18.65%

10 Years

▲14.41%

Lincoln Pharmaceuticals Share Price Today


As of 22 Apr 2026, Lincoln Pharmaceuticals share price is ₹608.2. The stock opened at ₹625 and had closed at ₹616 the previous day. During today’s trading session, Lincoln Pharmaceuticals share price moved between ₹603.10 and ₹634.50, with an average price for the day of ₹618.80. Over the last 52 weeks, the stock has recorded a low of ₹440.00 and a high of ₹677.00. In terms of performance, Lincoln Pharmaceuticals share price has increased by 16.2% over the past six months and has increased by 5.33% over the last year.

Lincoln Pharmaceuticals Stock Performance

1W Return5.70
1Y Return5.96
Today's Low603.1
Prev. Close616.05
Mkt Cap (Cr.)1,218.11
1M Return1.29
3Y Return50.76
52-Week High677
Open624.95
PE Ratio13.85
6M Return15.29
Today's High634.5
52-Week Low440
Face Value10

Lincoln Pharmaceuticals Company background

Founded in: 1995
Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. 95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The focused area includes antiinfective, respiratory system, gynecology, cardio CNS, antidiabetic, anti malaria, among others.The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals.The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake inhouse testing of its products for better quality control and RD. It came out with a public issue in Feb.96 to partfinance its project.The Company launched Next Generation Progesterone Therapy ProlinSpray during the year 2018. During the year 202122, Lincoln Parenteral Limited, an erstwhile subsidiary, merged with the Company through Scheme of Amalgamation and Lincoln Parenteral Limited ceased to be a subsidiary of the Company. The Company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products in 2022. The Company commenced commercial production in Mehsana in FY 2025.

Lincoln Pharmaceuticals Financial Highlights


For the full year FY2025–2026, revenue reached ₹645.71 crore and profit touched at ₹82.35 crore.
Read More
Lincoln Pharmaceuticals SIP Return Calculator
₹5,000
Over the past
Total Investment of ₹3,00,000
Monthly SIP of ₹5,000 would have become ₹4,97,488 in 5 years with a gain of ₹1,97,488 (+65.83%)
Start SIP

Lincoln Pharmaceuticals Fundamental

Market Cap (in crs)

1,218.11

Face Value

10

Turnover (in lacs)

358.67

Key Metrics

Qtr Change %
38.22% Gain from 52W Low
31.9
Dividend yield 1yr %
Below industry Median
0.3

Lincoln Pharmaceuticals Key Financials

View more
Loading chart...
Lincoln Pharmaceuticals Quarterly Revenue
Lincoln Pharmaceuticals Yearly Revenue
Lincoln Pharmaceuticals Quarterly Net Profit/Loss
Lincoln Pharmaceuticals Yearly Net Profit/Loss

Lincoln Pharmaceuticals Result Highlights

  • Lincoln Pharmaceuticals reported a 6.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 16.7%.

  • Its expenses for the quarter were up by 3.5% QoQ and 15.7% YoY.

  • The net profit increased 43.1% QoQ and increased 37.7% YoY.

  • The earnings per share (EPS) of Lincoln Pharmaceuticals stood at 14.28 during Q3 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Lincoln Pharmaceuticals Technical Analysis

Moving Averages Analysis
608.15
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5 EMA
599.00
10 EMA
591.10
12 EMA
589.90
20 EMA
588.50
26 EMA
587.40
50 EMA
576.40
100 EMA
558.40
200 EMA
556.30
Delivery & Volume
Loading chart...

Delivery Volume %

Day

43.10%

Week

47.30%

Month

53.20%

Delivery & Volume

Resistance & Support

615.25
Pivot
Resistance
First Resistance
627.40
Second Resistance
646.65
Third Resistance
658.80
Support
First Support
596
Second support
583.85
Third Support
564.60
Relative Strength Index
56.34
Money Flow Index
68.19
MACD
2.56
MACD Signal
-0.86
Average True Range
26.95
Average Directional Index
25.64
Rate of Change (21)
0.97
Rate of Change (125)
15.32

Lincoln Pharmaceuticals Peer comparison

Compare

Lincoln Pharmaceuticals Shareholding Pattern

Promoter
49.8%
Foreign Institutions
5.2%
Domestic Institutions
1.1%
Public
43.9%

Lincoln Pharmaceuticals FII Holdings & DII Holdings

Lincoln Pharmaceuticals Latest News

16 APR 2026

Lincoln Pharmaceuticals - 531633 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

06 APR 2026

Lincoln Pharmaceuticals - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

25 MAR 2026

Lincoln Pharmaceuticals - 531633 - Closure of Trading Window

View More

Lincoln Pharmaceuticals Share Price FAQs

Lincoln Pharmaceuticals share price is ₹608.15 in NSE and ₹607.2 in BSE as on 21/4/2026.

Lincoln Pharmaceuticals share price in the past 1-year return was 5.95. The Lincoln Pharmaceuticals share hit a 1-year low of Rs. 440 and a 1-year high of Rs. 677.

The market cap of Lincoln Pharmaceuticals is Rs. 1218.11 Cr. as of 21/4/2026.

The PE ratios of Lincoln Pharmaceuticals is 13.85 as of 21/4/2026.

The PB ratios of Lincoln Pharmaceuticals is 1.69 as of 21/4/2026

You can easily buy Lincoln Pharmaceuticals shares in Kotak Neo by opening a demat account and getting the KYC documents verified online.

The 52-week high and low of Lincoln Pharmaceuticals share price is ₹677 and ₹440 as of 21/4/2026.

Please be aware that Lincoln Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.